Roche’s rheumatoid arthritis drug Actemra shows no benefit in COVID-19 pneumonia

pharmafile | June 18, 2020 | News story | Research and Development Actemra, COVID-19, Roche, coronavirus 

Hope is waning around the efficacy of Roche’s Actemra (tocilizumab) following the release of results from an Italian study focusing on the use of the drug in patients with early-stage COVID-19 pneumonia.  

The anti-inflammation therapy, traditionally used as a treatment for rheumatoid arthritis, failed to show clinical benefit fir patients in reducing severe respiratory symptoms, visits to intensive care, or mortality compared to standard of care.

The study only managed to enrol 126 participants across 24 medical centres in Italy – less than half of the intended total number – and was stopped prematurely after an interim analysis ruled that continuing the trial would not reveal any further clinical benefit in the drug. Full results of the study are due to be presented shortly.

However, far from giving up on the drug’s potential benefit in treating COVID-19, Roche is pushing ahead with a study to evaluate the drug in severe pneumonia in patients with the novel coronavirus.

Advertisement

The investigators of the failed study are optimistic that Actemra may still show benefit in some specific patients evaluated in the trial, noting: “Although not effective in all patients with COVID-19 pneumonia, it is possible that selected subgroups of patients may have a better response to the drug.”

Matt Fellows

Related Content

covid_cell

COVID-19 vaccine eligibility creates challenges for UK pharmacies

Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …

alzheimers_brain

Roche receives CE Mark for blood test to help rule out Alzheimer’s

Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …

The Gateway to Local Adoption Series

Latest content